Vaccines against Streptococcus pneumoniae serotype 4

Patent metadata

Field	Value
Publication number	US-10188718-B2
Application number	US-201515534676-A
Country	US
Kind code	B2
Filing date	May 15, 2015
Priority date	Dec 12, 2014
Publication date	Jan 29, 2019
Grant date	Jan 29, 2019

Abstract

The present invention relates to synthetic saccharides of general formula (I) that are related to Streptococcus pneumoniae serotype 4 capsular polysaccharide and conjugates thereof. Said conjugate and a pharmaceutical composition containing said conjugate are useful for prevention and/or treatment of diseases associated with Streptococcus pneumoniae , and more specifically of diseases associated with Streptococcus pneumoniae serotype 4. Furthermore, the synthetic saccharides of general formula (I) are useful as marker in immunological assays for detection of antibodies against Streptococcus pneumoniae bacteria.

First claim

The invention claimed is:

1. A saccharide of general formula (I)
V*—[U x+3 —U x+2 —U x+1 —U x ] n -V—O-L-NH 2   (I)

wherein
x is an integer selected from 1, 2, 3 and 4;
n is an integer selected from 1, 2 and 3;

—V— represents a bond, —U x+3 —, —U x+3 —U x+2 — or —U x+3 —U x+2 —U x+1 —;
V*— represents H—, H—U x , H—U x+1 —U x —, H—U x+2 —U x+1 —U x ; and
L represents a linker;
or a diastereoisomer or a pharmaceutically acceptable salt thereof.

2. The saccharide according to claim 1 of general formula (II)
V*—[U x+3 —U x+2 —U x+1 —U x ] n —O-L-NH 2   (II)

wherein x, n, L, U x , U x+1 , U x+2 , U x+3 and V* have the meanings as defined in claim 1 .

3. The saccharide according to claim 1 of general formula (III)
V*—[U x+3 —U x+2 —U x+1 —U x ] n —U x+3 —O-L-NH 2   (III)

wherein x, n, L, U x , U x+1 , U x+2 , U x+3 and V* have the meanings as defined in claim 1 .

4. The saccharide according to claim 1 of general formula (IV)
V*—[U x+3 —U x+2 —U x+1 —U x ] n —U x+3 —U x+2 —O-L-NH 2   (IV)

wherein x, n, L, U x , U x+1 , U x+2 , U x+3 and V* have the meanings as defined in claim 1 .

5. The saccharide according to claim 1 of general formula (V)
V*—[U x+3 —U x+2 —U x+1 —U x ] n —U x+3 —U x+2 —U x+1 —O-L-NH 2   (V)

wherein x, n, L, U x , U x+1 , U x+2 , U x+3 and V* have the meanings as defined in claim 1 .

6. The saccharide according to claim 1 , wherein x represents 1; and V*— represents H—.

7. A conjugate of general formula (VII)
[V*—(U x+3 —U x+2 —U x+1 —U x ) n —V—O-L-NH—W] c —NH—CRM 197   (VII)

wherein
x is an integer selected from 1, 2, 3 and 4;
n is an integer selected from 1, 2 and 3;

—V— represents a bond, —U x+3 —, —U x+3 —U x+2 — or —U x+3 —U x+2 —U x+1 —;
V*— represents H—, H—U x , H—U x+1 —U x , H—U x+2 —U x+1 —U x —; and
L represents a linker;
c is comprised between 2 and 18;
—W— is selected from:

a is an integer selected from 1, 2, 3, 4, 5, 6, 7, 8, 9 and 10,
b is an integer selected from 1, 2, 3 and 4, and
or a diastereoisomer or a pharmaceutically acceptable salt thereof.

8. A method for raising a protective immune response in a human or an animal host against Streptococcus pneumoniae serotype 4 comprising administering a therapeutically effective amount of the saccharide according to claim 1 to the human or the animal host.

9. A method for preventing or treating in a human or an animal host a disease comprising administering a therapeutically effective amount of the saccharide according to claim 1 to the human or animal host, wherein the disease is associated with bacteria that contain in their capsular polysaccharide one of the following saccharide fragments:
-3)-β-D-ManNAc-(1, 3)-α-L-FucNAc-(1, 3)-α-D-GalNAc-(1, 4)-α-D-Gal-2,3(S)Pyr-(1-;
-4)-α-D-Gal-2,3(S)Pyr-(1, 3)-β-D-ManNAc-(1, 3)-α-L-FucNAc-(1, 3)-α-D-GalNAc-(1-;
-3)-α-D-GalNAc-(1, 4)-α-D-Gal-2,3(S)Pyr-(1, 3)-β-D-ManNAc-(1, 3)-α-L-FucNAc-(1-; or
-3)-α-L-FucNAc-(1, 3)-α-D-GalNAc-(1, 4)-α-D-Gal-2,3(S)Pyr-(1, 3)-β-D-ManNAc-(1-.

10. The method according to claim 9 , wherein the bacteria is Streptococcus pneumoniae serotype 4.

11. The method according to claim 9 , wherein the diseases associated with bacteria are selected from pneumonia, meningitis, otitis media, bacteremia and acute exacerbation of chronic bronchitis, sinusitis, arthritis and conjunctivitis.

12. A pharmaceutical composition comprising the conjugate according to claim 7 , together with at least one pharmaceutically acceptable adjuvant and/or excipient.

13. A method for detecting antibodies against bacteria comprising contacting a sample with the saccharide according to claim 1 , wherein the bacteria contain in their capsular polysaccharide one of the following saccharide fragments:
-3)-β-D-ManNAc-(1, 3)-α-L-FucNAc-(1, 3)-α-D-GalNAc-(1, 4)-α-D-Gal-2,3(S)Pyr-(1-;
-4)-α-D-Gal-2,3(S)Pyr-(1, 3)-β-D-ManNAc-(1, 3)-α-L-FucNAc-(1, 3)-α-D-GalNAc-(1-;
-3)-α-D-GalNAc-(1, 4)-α-D-Gal-2,3(S)Pyr-(1, 3)-β-D-ManNAc-(1, 3)-α-L-FucNAc-(1-; or
-3)-α-L-FucNAc-(1, 3)-α-D-GalNAc-(1, 4)-α-D-Gal-2,3(S)Pyr-(1, 3)-β-D-ManNAc-(1-;
and wherein the saccharide is a marker in an immunological assay.

14. The saccharide according to claim 2 , wherein x represents 1; and V*— represents H—.

15. The saccharide according to claim 3 , wherein x represents 1; and V*— represents H—.

16. The saccharide according to claim 4 , wherein x represents 1; and V*— represents H—.

17. The saccharide according to claim 5 , wherein x represents 1; and V*— represents H—.

18. The conjugate according to claim 7 , wherein x represents 1; and V*— represents H—.

19. The conjugate according to claim 18 , wherein —W— represents

and a is an integer selected from 2, 3, 4, 5 and 6.

20. The conjugate of claim 19 , wherein -L- represents —(CH 2 ) o —; and o is an integer selected from 2, 3, 4, 5 and 6.

21. The conjugate of claim 20 , wherein c is comprised between 8 and 12; and n represents 1.

22. A method for raising a protective immune response in a human or an animal host against Streptococcus pneumoniae serotype 4 comprising administering a therapeutically effective amount of the conjugate according to claim 7 to the human or the animal host.

23. A method for preventing or treating in a human or an animal host a disease comprising administering a therapeutically effective amount of the conjugate according to claim 7 to the human or the animal host, wherein the disease is associated with bacteria that contain in their capsular polysaccharide one of the following saccharide fragments:
-3)-β-D-ManNAc-(1, 3)-α-L-FucNAc-(1, 3)-α-D-GalNAc-(1, 4)-α-D-Gal-2,3(S)Pyr-(1-;
-4)-α-D-Gal-2,3(S)Pyr-(1, 3)-β-D-ManNAc-(1, 3)-α-L-FucNAc-(1, 3)-α-D-GalNAc-(1-;
-3)-α-D-GalNAc-(1, 4)-α-D-Gal-2,3(S)Pyr-(1, 3)-β-D-ManNAc-(1, 3)-α-L-FucNAc-(1-; or
-3)-α-L-FucNAc-(1, 3)-α-D-GalNAc-(1, 4)-α-D-Gal-2,3(S)Pyr-(1, 3)-β-D-ManNAc-(1-.

24. The method according to claim 23 , wherein the diseases associated with bacteria are selected from pneumonia, meningitis, otitis media, bacteremia and acute exacerbation of chronic bronchitis, sinusitis, arthritis and conjunctivitis.

25. A pharmaceutical composition comprising the saccharide according to claim 1 , together with at least one pharmaceutically acceptable adjuvant and/or excipient.

Assignees

• Max Planck Gesellschaft

Inventors

• Seeberger Peter H
• Pereira Claney Lebev
• Anish Chakkumkal
• Geissner Andreas

Classifications

• A61P31/04

  Antibacterial agents · CPC title

• A61P29/00

  Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] · CPC title

• A61P27/16

  Otologicals · CPC title

• A61P27/02

  Ophthalmic agents · CPC title

• A61P19/02

  for joint disorders, e.g. arthritis, arthrosis · CPC title